Hong Kong at a glance
- Population
- 7.5 million 2025
- Life expectancy at birth
- 85.4 years, 2024
- People aged 65 and over
- 23.7 % of people, 2025
Updated
Reviewed by Vidhi Upadhyay
Hong Kong Burn Care Market Analysis Industry Trends and Forecast to 2034: Segmented by (By Product Type, By Depth of Burn, By End User, By Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
| Market size, 2025 | Researched figures come with the full report |
|---|---|
| Forecast, 2034 | Researched figures come with the full report |
| Growth (CAGR), 2025–2034 | Researched figures come with the full report |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Product type, depth of burn and end user (see all) |
| Key players | Smith & Nephew, Molnlycke Health Care, Johnson & Johnson, ConvaTec Inc., 3M Company and 2 more (see all) |
| Regulator in Hong Kong | Drug OfficeSource: Drug Office, Department of Health. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Burns are injuries that happen to the body tissues as a result of heat, chemicals, electricity, radiation, and the sun. More than 400,000 people look for medical attention due to accidental burns annually in the United States. The first-degree burns and majority of the second-degree burn can be managed using home remedies. Third-degree burns are as dangerous as the third, and any misuse of the affected area can lead to death; therefore, it should be treated by specialists. Burn deaths have also increasingly been described in many high-income countries, and the current rate for child burn deaths in LMICs is above 7 times that of high-income countries. Patients receive morphine as well as anti-anxiety agents; the latter are typically administered when dressing changes are scheduled. When the patient is not going to a burn centre, the team might use topical agents which will also help in wound care, these include bacitracin and silver sulfadiazine (Silvadene) creams or ointments.
The burn care market is growing due to increasing cases of burns and development of new products including bioengineered skin substitutes and advanced dressings. While reimbursement schemes implemented by governments add affordability to costly treatments, high costs and scarcity of human cadres remain an issue. Inequalities in patients’ reimbursements also negatively impact their ability to access new and effective medical treatments. The COVID-19 outbreak affected burn care services, but the market recovered with a focus on updating standards for better practice and increasing access to enhanced care due to organizations such as ABA and WHO.
The increase in burn incidence among patients worldwide, including those from LMICs, is another factor as it estimated causes 180,000 deaths per year. Due to this there have been high demand for skin grafts and various products for the management of burns which are effective in the overall management and healing. Development in technology is shifting towards innovative dressings and biological agents, which directly encourage the expansion of the novel products into the market due to the improved outcomes of the latter as a factor of the former. The trends in adoption of less invasive surgeries, combined with positive government policies and reimbursement practices are also driving the market. Secondly, the growth of the burn care market is due to the enhanced patient knowledge of available treatments for burn victims.
Burn market has tremendous potential in emerging economies like Asia, Latin America, and Africa as these countries have set higher growth rates in their healthcare budgets compared to developed nations, hence revealing a high demand for burns care products in countries like China, India, Brazil, and Mexico. Advancements in tissue engineering and regenerative medicine offer an even more useful application of skin grafts and their substitutes. Moreover, systematic advancements in the field such as smart wound dressings and bioactive dressing also show potential for better management of patient symptoms and enhanced healing time. With development of healthcare facilities and strengthening of the population’s consciousness, especially in the emergent states, the need for elaborate burn treatment options will emerge.
The market for burn care is greatly influenced by factors such as the expensive products used in the treatment of burns that may act as restraints to the market. Lack of skilled human capital also presents a major challenge in terms of timely and adequate treatment of burn injuries, especially given that the COVID-19 pandemic impacted emergency response, as well as surgical and rehabilitation services. Also, differences in reimbursement policies reduce opportunities for infected patients to receive breakthrough treatments, which are even more challenges for recovery. The pandemic also affected the market through reduced admission for minor burn injuries and a decline in burn care surgeries.
June 2024, Indian Army launches first-of-its-kind skin bank for treatment of severe burn injuries.
May 2025, FDA has approved three hydrogel dressings for diabetic wound care: Apligraf, Leucopatch, and Regranex.
March 2025, Convatec received FDA clearance for its device designed to manage complex surgical wounds and burns. InnovaBurn placental extracellular matrix medical device will serve as advanced ECM technology for partial-thickness, second-degree burns.
December 2022, MediWound received FDA clearance for its NexoBrid. It is used for the treatment of severe thermal burns in adults.
June 2021, FDA Approves StrataGraft for the Treatment of Adults with Thermal Burns.
September 2021, Omeza Receives FDA Clearance for Omeza® Collagen Matrix. First Drug Device Combination of Its Kind for Chronic Wound Care.
March 2022, Essity Acquires Advanced Wound Care Company. Purchase of Hydrofera supports company's priority to grow through acquisitions in Medical Solutions.
Pharmaceutical products must be registered with the Pharmacy and Poisons Board before sale, through the Drug Office of the Department of Health.[1] Public hospitals and clinics, run by the Hospital Authority, are heavily subsidised by the government.[2]
[1] Drug Office, Department of Health. Checked 14 Nov 2026.
[2] Hospital Authority. Checked 14 Nov 2026.
Reimbursement schemes, where the government compensates for over 70% of the burn treatment costs, aids in the implementation of innovative therapies. Still, in equality of insurance coverage and reimbursement for providers hinders patient access to new therapies, such as advanced dressings and biologics. Professional bodies like the American Burn Association and the WHO are vital in lobbying for better reimbursement policies and increasing awareness of burn care. Affordability also continues to be a challenge to the adoption of approved treatment such as StrataGraft. The market is also witnessing the shift of focus towards technology progression to enhance the standard of healthcare facilities with the government’s backing. With the gradual easing of healthcare systems from the impact of COVID-19, there has been a renewed effort to improve burn care and reimbursement strategies.
What doctors and scientists are doing in Burn Care right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 9 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.
From our blog
Hong Kong · 11 shared keywords
Hong Kong · 1 shared keyword
Hong Kong · 1 shared keyword
Hong Kong · 1 shared keyword
Hong Kong · 1 shared keyword
Hong Kong · 1 shared keyword
Medical Devices · Hong Kong
Medical Devices · Hong Kong
Healthcare Services · Hong Kong
Healthcare Services · Hong Kong
Healthcare Services · Hong Kong
Medical Devices · Hong Kong